Claro Advisors LLC Has $239,000 Holdings in Biogen Inc. $BIIB

Claro Advisors LLC trimmed its stake in Biogen Inc. (NASDAQ:BIIB) by 33.9% in the second quarter, HoldingsChannel.com reports. The firm owned 1,902 shares of the biotechnology company’s stock after selling 975 shares during the period. Claro Advisors LLC’s holdings in Biogen were worth $239,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Vision Financial Markets LLC acquired a new stake in shares of Biogen in the first quarter valued at about $27,000. Greykasell Wealth Strategies Inc. bought a new stake in Biogen in the first quarter valued at approximately $27,000. Zions Bancorporation National Association UT acquired a new stake in Biogen during the 1st quarter valued at approximately $29,000. Concord Wealth Partners raised its holdings in Biogen by 100.0% during the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 114 shares during the last quarter. Finally, Private Trust Co. NA lifted its position in shares of Biogen by 74.8% in the 1st quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 98 shares during the period. 87.93% of the stock is owned by institutional investors.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 517 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the transaction, the insider directly owned 5,772 shares of the company’s stock, valued at $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is currently owned by corporate insiders.

Biogen Price Performance

BIIB stock opened at $156.74 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79. The company’s 50-day moving average is $145.59 and its 200-day moving average is $134.51. The stock has a market capitalization of $22.99 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 1.17 and a beta of 0.10. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $176.95.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business had revenue of $2.53 billion during the quarter, compared to analyst estimates of $2.34 billion. During the same period in the previous year, the company posted $4.08 EPS. The firm’s revenue was up 2.8% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Equities research analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BIIB. Guggenheim increased their price objective on shares of Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Sanford C. Bernstein increased their price target on Biogen from $155.00 to $157.00 and gave the stock a “market perform” rating in a report on Monday. BMO Capital Markets lifted their price objective on Biogen from $128.00 to $150.00 in a research report on Friday, October 31st. Morgan Stanley upped their target price on Biogen from $144.00 to $149.00 and gave the company an “equal weight” rating in a research report on Friday, October 10th. Finally, Wall Street Zen cut Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 1st. Ten research analysts have rated the stock with a Buy rating and eighteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $177.46.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.